Mipasetamab (CAS: 2361055-48-1)
Mipasetamab is a humanized IgG1κ monoclonal antibody that specifically targets AXL, a tyrosine kinase receptor and member of the TAM receptor family. By inhibiting AXL signaling pathways, Mipasetamab may reduce tumor growth and metastasis.
Key Features:
- Target Specificity: Binds specifically to AXL, a tyrosine kinase receptor involved in cell survival and migration.
- Mechanism of Action: Inhibits AXL signaling, which can help reduce tumor progression and metastasis.
- Therapeutic Potential: Investigated for treating cancers with elevated AXL expression, which are associated with poor prognosis.
Applications:
- Cancer Research: Used to explore the role of AXL in tumor progression and metastasis.
- ADC Development: Involved in the synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC) with anti-tumor activity.
- Therapeutic Development: ADCT-601 is being studied for its potential to treat cancers with high AXL expression.
Handling and Storage:
- Formulation: Available as a research-grade biosimilar antibody.
- Storage: Store at -20°C in a dry, light-protected environment.
- Precautions: Use personal protective equipment and ensure proper ventilation during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
